Banque Transatlantique SA Acquires Shares of 485,123 Zoetis Inc. (NYSE:ZTS)

Banque Transatlantique SA purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 485,123 shares of the company's stock, valued at approximately $79,041,000. Zoetis makes up 1.9% of Banque Transatlantique SA's investment portfolio, making the stock its 15th largest holding. Banque Transatlantique SA owned 0.11% of Zoetis at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC increased its position in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. boosted its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC bought a new stake in shares of Zoetis during the fourth quarter worth approximately $30,000. Murphy & Mullick Capital Management Corp bought a new stake in shares of Zoetis during the fourth quarter worth approximately $44,000. Finally, Asset Planning Inc acquired a new position in Zoetis in the fourth quarter valued at approximately $58,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 4.2 %

ZTS traded up $6.28 during trading on Wednesday, reaching $156.15. The company had a trading volume of 4,453,847 shares, compared to its average volume of 2,479,023. The business's fifty day moving average price is $157.87 and its 200 day moving average price is $166.69. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a market cap of $69.67 billion, a P/E ratio of 28.55, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same period in the prior year, the business earned $1.38 EPS. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio is currently 36.56%.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Piper Sandler increased their price target on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Finally, Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Zoetis presently has an average rating of "Buy" and an average price target of $213.56.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.